Related references
Note: Only part of the references are listed.Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
Sergey Yagoda et al.
CNS SPECTRUMS (2021)
Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
Carla Rognoni et al.
CLINICAL DRUG INVESTIGATION (2021)
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension
Rene S. Kahn et al.
SCHIZOPHRENIA RESEARCH (2021)
184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers
William Martin et al.
CNS SPECTRUMS (2020)
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
Christoph U. Correll et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial
Mary F. Brunette et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study
Steven G. Potkin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
Jacobi I. Cunningham et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
Lei Sun et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
William F. Martin et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
Lei Sun et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia
Giselli Scaini et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2018)
Glucose metabolism alterations in patients with bipolar disorder
Gianluca Rosso et al.
JOURNAL OF AFFECTIVE DISORDERS (2015)
Weight Gain and Changes in Metabolic Variables following Olanzapine Treatment in Schizophrenia and Bipolar Disorder
Leslie Citrome et al.
CLINICAL DRUG INVESTIGATION (2011)